Strmsek Ziga, Kunej Tanja
Department of Animal Science, Biotechnical Faculty, University of Ljubljana, Groblje 3, 1230, Domzale, Slovenia.
Discoveries (Craiova). 2014 Jun 30;2(2):e18. doi: 10.15190/d.2014.10.
There is an increasing research interest regarding deregulation of microRNA (miRNA) expression by DNA methylation in cancer. The aim of this study was to integrate data from publications and identify miRNA genes shown to be silenced in the highest number of cancer types and thus facilitate biomarker and therapeutic development. We integrated relevant data from 104 published scientific articles. The following databases and bioinformatics tools were used for the analysis: miRBase, miRNA Genomic Viewer, MultAlin, miRNA SNiPer, TargetScan, Ensembl, MethPrimer, TarBase, miRecords, and ChIPBase. Among 2578 currently known human miRNAs and 158 known to be regulated by DNA methylation, miR-34 gene family (miR-34a, -34b, and -34c) was shown to be silenced by DNA methylation in the highest number of cancer types. Consequently, we developed the miR-34 gene family regulatory atlas, consisting of its upstream regulators and downstream targets including transcription factor binding sites (TFBSs), CpG islands, genetic variability and overlapping QTL. MicroRNA-34 gene family has a potential as a cancer biomarker and target for epigenetic drugs. This potential has already been recognized as MRX34 is well into phase I studies. The developed miR-34 gene family regulatory atlas presented in this study provides a starting point for further analyses and could thus facilitate development of therapeutics.
关于DNA甲基化导致的微小RNA(miRNA)表达失调在癌症中的研究兴趣与日俱增。本研究的目的是整合来自出版物的数据,识别在最多癌症类型中显示沉默的miRNA基因,从而促进生物标志物和治疗方法的开发。我们整合了104篇已发表科学文章中的相关数据。使用了以下数据库和生物信息学工具进行分析:miRBase、miRNA基因组浏览器、MultAlin、miRNA SNiPer、TargetScan、Ensembl、MethPrimer、TarBase、miRecords和ChIPBase。在目前已知的2578个人类miRNA和158个已知受DNA甲基化调控的miRNA中,miR-34基因家族(miR-34a、-34b和-34c)在最多癌症类型中显示因DNA甲基化而沉默。因此,我们绘制了miR-34基因家族调控图谱,包括其上游调节因子和下游靶点,如转录因子结合位点(TFBS)、CpG岛、遗传变异性和重叠数量性状位点。微小RNA-34基因家族有潜力成为癌症生物标志物和表观遗传药物的靶点。这种潜力已经得到认可,因为MRX34已顺利进入I期研究。本研究中绘制的miR-34基因家族调控图谱为进一步分析提供了一个起点,从而有助于治疗方法的开发。